Search Browse Earnings

NewcelX Ltd. — SlamSEC

NewcelX Ltd.

Nasdaq:NCEL

Pharmaceutical Preparations·ZURICH

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

-$15.5M

FY 2024

Net Income

-$16.5M

FY 2024

EPS (Diluted)

-$33.52

FY 2024

Stock Price

$2.74

-3.9%

2026-03-09

52W Range

$1.89 – $30.80

P/E Ratio

-0.1x

Market Cap

$8.7M

Cash

$897,680

FY 2024

Total Debt

$2.9M

FY 2021

Net Debt

$2.0M

FY 2021

Enterprise Value

$10.7M

Debt / EBITDA

-0.1x

FY 2024

EV / EBITDA

-0.7x

Employees

—